Denny Hamlin, FedEx #11 NASCAR Sprint Cup Driver, announced today that the Denny Hamlin Foundation will give $150,000 to Children’s Hospital of Richmond at VCU and the Cystic Fibrosis Foundation to help fund cystic fibrosis research and clinical trials for cystic fibrosis in Richmond.

“This is a big day for the Denny Hamlin Foundation,” Hamlin said. “It is exactly what I envisioned the foundation doing when I started it five years ago, and we’ve worked hard to get to a point where we can give this kind of gift.

VCU is one of the country’s leading research centers for CF, and it is right here in our own backyard,” Hamlin said. “I am honored to support such an outstanding organization with people who are making a difference in the world.

The Denny Hamlin Foundation will give $50,000 for the next three years for CF research and to support the Children’s Hospital of Richmond at VCU Therapeutics Development Center, which conducts all phases of clinical trials for potential CF therapies.

“I have been caring for children and adults with cystic fibrosis for more than 35 years and my laboratory has been studying CF and developing new therapies for over 25 years,” said Bruce Rubin, M.D., professor and chair of the VCU Department of Pediatrics and physician-in-chief of Children’s Hospital of Richmond at VCU. “This generous donation will help accelerate our ability to bring these therapies to our patients, and the newly established Denny Hamlin Foundation Summer Scholars program will help us train the next generation of CF research scientists.

CF is a genetic disease that affects about 30,000 children and adults in the United States and about 70,000 worldwide. CF causes chronic infections in the lungs and inadequate digestion of nutrients. There is no cure for CF, but medical advances have doubled the life expectancy of children in the last 30 years and increased the overall median age of survival to 38.

According to Rubin, CF research and care has much in common with NASCAR racing. “It is the talented pit crew that makes sure it all works. My pit crew is the many amazing scientists in the labs and the fantastic clinical care team. And just as sponsors keep the wheels on the car and gas in the tank, sponsorship of our CF care and research center by the Denny Hamlin Foundation will allow us to compete at the international level as we race to find a cure for CF.”

Hamlin began donating money from his race winnings to the Cystic Fibrosis Foundation when he started racing go karts as a child.
## New Grants & Contracts Awarded

Congratulations to the following Principal Investigators who were awarded grants and contracts in the first half of 2012!

<table>
<thead>
<tr>
<th>Name</th>
<th>Department</th>
<th>Description</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Francis, Gary L.</td>
<td>Pediatrics</td>
<td>A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents with Type 1 Diabetes Mellitus</td>
<td>Novo Nordisk Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Schmidt, Howard J.</td>
<td>Pediatrics</td>
<td>Therapeutics Development Center</td>
<td>2 2012</td>
</tr>
<tr>
<td>Godder, Kamar</td>
<td>Pediatrics</td>
<td>An Open-label, Extension Study to Assess the Long-term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children Who Completed the OTR3001 Study</td>
<td>Purdue Pharma LP</td>
</tr>
<tr>
<td>Irani, Anne-Marie</td>
<td>Pediatrics</td>
<td>A Prospective, Randomized, Double-Blind Controlled Study to Evaluate the Nutritional Safety (Growth) and Hypoa1lergenicity of an Amino Acid Based Formula With Prebiotics and Probiotics in Infants Diagnosed With Cow Milk Allergy, With or Without Other Food Allergies</td>
<td>SHS International Ltd./ Nutricia North America</td>
</tr>
<tr>
<td>Irani, Anne-Marie</td>
<td>Pediatrics</td>
<td>Phase IV Study to Evaluate the Persistency of Asthma With or Without Xolair After Long Term Therapy</td>
<td>Genentech, Inc.</td>
</tr>
<tr>
<td>Francis, Gary L.</td>
<td>Pediatrics</td>
<td>A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin IR or Metformin XR in Pediatric Patients with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin Alone</td>
<td>Bristol-Myers Squibb Company</td>
</tr>
<tr>
<td>Rozycki, Henry J.</td>
<td>Pediatrics</td>
<td>TLR4 Function in Premature Lung Cells</td>
<td>Jeffress Memorial Trust</td>
</tr>
<tr>
<td>Rubin, Bruce K.</td>
<td>Pediatrics</td>
<td>An Observational Study to Evaluate the Relationship of Nasal Mucus Properties and Symptoms in Acute Rhinosinusitis</td>
<td>McNeil Consumer Healthcare</td>
</tr>
<tr>
<td>Rubin, Bruce K.</td>
<td>Pediatrics</td>
<td>The Effect of Humidification on Mucus Rheology</td>
<td>Fisher &amp; Paykel Healthcare, Ltd</td>
</tr>
<tr>
<td>Elsea, Sarah H.</td>
<td>Pediatrics</td>
<td>A cell culture model to detect drug-induced expression of RAI1</td>
<td>Smith-Magenis Research Foundation</td>
</tr>
<tr>
<td>Kumar, Santhosh</td>
<td>Pediatrics</td>
<td>A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum Pratense) Sublingual Tablet (SCH 697243) in Subjects Between 5 and 65 Years of Age, With a History of Grass Pollen-Induced Rhinoconjunctivitis, With or Without Asthma (Phase 3; Protocol No. P08067)</td>
<td>Merck &amp; Co.</td>
</tr>
<tr>
<td>Gupta, Anshu</td>
<td>Pediatrics</td>
<td>Role of advanced glycation end products (AGEs) in polycystic ovary syndrome (PCOS)</td>
<td>AD Williams.</td>
</tr>
</tbody>
</table>

Anyone with a grant application, or an inquiry or an idea is encouraged to call the Pediatric Research Office. We can help with regulatory document review and preparation (OSP, IRB, WIRB, IACUC), with budget preparation, with getting signatures or with finding resources within the University to help you accomplish your research goals. Call or email Jaime Petrasek or Henry Rozycki.


*W.B. Moskowitz


*K Godder


*K Godder


Papers in print or online before publication will be included in the next newsletter. If any publications were missed, please email Henry Rozycki and we will include them in the next newsletter. Congratulations to all the authors of these 27 publications!
CHOR@VCU on the move!

Presentations to National & International Meetings

**Houston TX** - Society of Critical Care Medicine Conference Feb 4-8, 2012

Azadeh Fayazi, Gary Francis, Mark Marinello, Sue Sreedhar, Leroy Thacker, Lorin Bachmann. Is Vitamin D Deficiency Associated with Critical Illness in Children?


Byrne MD, King AB, Speich JE, Klausner AP, Ratz PH. A new method for objective analysis of detrusor rhythmic contraction.


Klausner AP, King AB, Rogman A, Speich JE, Byrne MD, Ratz PH. Prostanoid profiling using ion-spray tandem mass spectrophotometry: a potential new modality for overactive bladder diagnosis and sub-typing.

**Tenerife, Spain** - International Course in Pediatric Pulmonology, Mar 22-26, 2012


**San Diego CA** - Experimental Biology. Apr 21-25, 2012


**Boston MA** - Pediatric Academic Societies. April 28-May 1, 2012


Bean, MK., Biskobing, DM., Francis, GL, Wickham, EW. Motivational Interviewing in Healthcare: Results of a Brief Training in Endocrinology.


Carr C, Wijesooriya NR, Francis G, Gennings C, Wickham E. Urinary Phthalate Levels and Obesity in U.S. Children: Are They Related?

Astoria M, Karam S, Magill C, Rozycki HJ, Moores R. Cardiac-Specific Troponin as a Predictor of Outcome in Neonatal ECMO.


Fox JR, Rozycki HJ. Should Premature Infants Who Receive Prophylactic Surfactant Be Routinely Evaluated and Treated for Sepsis?

Bunchman TE. Current State of Extracorporeal Renal Replacement Therapy

Bunchman TE. Devices To Support Neonatal AKI Injury.

Tanabe T, Shimokawaji T, Kanoh S, Rubin BK. IL-33 Increases IL-8 Secretion From Human Airway Goblet Cells

Mikita K, Kanoh S, Tanabe T, Kawano S, Hara Y, Fujikura Y, Maeda T, Kawana A, Rubin BK, Tokorozawa JP. Macrolides Inhibit Interleukin-13-Induced Goblet Cell Hyperplasia In Human Airway Cells

Kanoh S, Tanabe T, Rubin BK. Dapsone Attenuates IL-13-Induced MUC5AC Expression And Goblet Cell Differentiation In Human Bronchial Epithelial Cells

Tanabe T, Shimokawaji T, Kanoh S, Rubin BK. Secretory Phospholipases A₂ Are Produced In Ciliated Airway Cells And Increase Goblet Cell MUC5AC

Rozycki HJ, Brock A, Webb-Parker S, Tanabe T. Increased CXCL2 Production From Mouse Type II Alveolar Epithelial Cells In Response To The Alarmin HMGB1

Rubin BK. 1) Professor’s Rounds Plastic Bronchitis. 2) Symposium Pathways to drug development.

Atlanta GA ⃣ American Urological Association, May 19-23, 2012

Ratz PH, Klausner AP, Speich JE. How might bladder filling phase contractile activity affect urgency and the power of voiding contraction?

San Francisco CA ⃣ American Society for Artificial Internal Organs. June 14-16, 2012

Downs EA, Moskowitz WB, Throckmorton AL. Intravascular Mechanical Cavopulmonary Assistance of 3-D Patient-Specific Fontan Configurations.

Throckmorton AL, Sciolino MG, Downs ES, Lopez-Isaza S, Moskowitz WB. Controlled Pitch-Adjustment of Impeller Blades for an Intravascular Blood Pump


There are currently more than eight clinical trials actively enrolling patients through the Pediatric Research Office. Several more not listed here are being done in the CRSU or within specific labs and clinical divisions. There is a web page dedicated to clinical research trials on the Department web site at [http://www.pediatrics.vcu.edu/research/patients.html](http://www.pediatrics.vcu.edu/research/patients.html). We plan to improve it by highlighting actively recruiting trials.

Even more exciting news is that there are 9 clinical trials in the pipeline and expected to begin enrolling patients beginning this fall.

<table>
<thead>
<tr>
<th>Investigator</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary L. Francis</td>
<td>Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes</td>
</tr>
<tr>
<td>Gary L. Francis</td>
<td>Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus</td>
</tr>
<tr>
<td>Gary L. Francis</td>
<td>A trial investigating the efficacy and safety of insulin degludec in children and adolescents with type 1 diabetes mellitus</td>
</tr>
<tr>
<td>Gary L. Francis</td>
<td>Type 1 Diabetes Trial Net</td>
</tr>
<tr>
<td>Kamar Godder</td>
<td>Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids</td>
</tr>
<tr>
<td>Linda Meloy</td>
<td>Preterm Infant Growth</td>
</tr>
<tr>
<td>Suzanne Lavoie</td>
<td>An Open-Label, Multicenter, Multiple-Dose Pharmacokinetic and 48-week safety and Efficacy Trial of Maraviroc in Combination with Optimized Background Therapy for the treatment of Antiretroviral-experienced CCR5-Tropic HIV-1 Infected Children 2-18 years of age</td>
</tr>
</tbody>
</table>

Clinical trials can be investigator-initiated or come from sponsors. If any help is required regarding:

- Feasibility, e.g. are there enough subjects?
- Resource identification
- Budget construction
- Regulatory requirements and documentation
- Protocol development
- Study implementation
- Finances
- Close-out
- Others

Please contact Jaime Petrasek or Henry Rozycki